Experts of the Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation together with the Association of International Pharmaceuticals Manufacturers, announced at the XI Telemedforum a significant achievement in digital healthcare in Russia for the first time. Experts have collaborated to create and test a method for evaluating Digital Medical Products and Services thoroughly.
A key result of this work was the creation of a national classification for implementation and a draft document for evaluating digital solutions, which will create a uniform standard for interaction between digital service developers and regulators based on evidence-based principles.
One important effect of this DMPS evaluation is the simplification of including digital solutions in mandatory health insurance rates. The transparency of this assessment system opens up opportunities for a comprehensive approach to treatment based on a "medicine + services" model.
This assessment system allows:
Clear rules for evaluation help governments and payers to choose only solutions that improve treatment outcomes, and regular monitoring of effectiveness is necessary after implementation to avoid degradation of AI models. Their diagnostic accuracy may decline over time.
Rules for evaluating DMPS and government reimbursement affect the success of drugs. This is important for medical decision-support systems (MDSs), which help physicians make accurate diagnoses and choose optimal treatments based on clinical recommendations.
Scientific significance of the project has been confirmed by publications in professional journals, such as:
International companies participating in this project are willing to be partners in implementing individual initiatives to develop digital healthcare in Russia, paying special attention to adapting global experience in evaluating healthcare technologies for Russian specifics.
A key result of this work was the creation of a national classification for implementation and a draft document for evaluating digital solutions, which will create a uniform standard for interaction between digital service developers and regulators based on evidence-based principles.
One important effect of this DMPS evaluation is the simplification of including digital solutions in mandatory health insurance rates. The transparency of this assessment system opens up opportunities for a comprehensive approach to treatment based on a "medicine + services" model.
This assessment system allows:
- Standardizing the introduction of new technologies
- Ensuring the effectiveness of solutions based on evidence
- Optimizing costs in the healthcare system
Clear rules for evaluation help governments and payers to choose only solutions that improve treatment outcomes, and regular monitoring of effectiveness is necessary after implementation to avoid degradation of AI models. Their diagnostic accuracy may decline over time.
Rules for evaluating DMPS and government reimbursement affect the success of drugs. This is important for medical decision-support systems (MDSs), which help physicians make accurate diagnoses and choose optimal treatments based on clinical recommendations.
Scientific significance of the project has been confirmed by publications in professional journals, such as:
- "Pharmacoeconomic" - https://www.pharmacoeconomics.ru/jour/article/view/1287/658
- "Medical Technologies: Evaluation and Selection" - https://www.mediasphera.ru/issues/meditsinskie-tekhnologii-otsenka-i-vybor/2026/1/1221906782026011011
International companies participating in this project are willing to be partners in implementing individual initiatives to develop digital healthcare in Russia, paying special attention to adapting global experience in evaluating healthcare technologies for Russian specifics.